Welcome!

News Feed Item

Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2014

Second quarter net earnings per diluted share are $0.88 including patent litigation settlement; revenues increase 1 percent to $779 million

PALO ALTO, Calif., April 23, 2014 /PRNewswire/ -- Varian Medical Systems (NYSE: VAR) today is reporting net earnings of $0.88 per diluted share in the second quarter of fiscal year 2014, including a $0.16 charge per diluted share related to a previously announced settlement of patent litigation.  Varian's company-wide revenues totaled $779 million for the second quarter of fiscal year 2014, up 1 percent from the year-ago quarter.  Varian ended the second quarter with a $2.8 billion backlog, up 2 percent from the end of the second quarter of fiscal year 2013.

"Gross orders rose strongly in our imaging components and proton businesses on top of mid-single-digit gains in Oncology Systems," said Dow R. Wilson, CEO of Varian Medical Systems.  "Revenues came in slightly ahead of expectations versus a strong year-ago comparison, and our overall growth strategy remained on track."

The company finished the second quarter of fiscal year 2014 with $939 million in cash and cash equivalents and $469 million of debt.  Cash flow from operations for the fiscal second quarter was $126 million.  During the quarter, the company spent $159 million to repurchase approximately 2 million shares of its common stock.

Oncology Systems
Oncology Systems' second quarter revenues totaled $603 million, up 4 percent from the same quarter of fiscal year 2013.  Second-quarter gross orders were $613 million, up 6 percent versus the year-ago quarter, with a 3 percent gain in North America and a 9 percent gain outside North America. Markets outside North America represented 58 percent of Oncology gross orders for the second quarter of fiscal year 2014. 

"Gross orders rose versus the year-ago quarter in North America with the help of good service growth.  New multi-year agreements with large hospital systems also contributed to gains in Oncology products and services," Wilson said.  "International orders increased with particular strength in Latin America and Australia that offset softness in Asia.  Initiatives to expand our radiosurgery business and stimulate replacement of aging Siemens units gained traction during the quarter."

Imaging Components
During the second quarter, the company consolidated its X-Ray Products and Security and Inspection Products businesses into a single Imaging Components segment to conform to an organizational change. Second quarter revenues for Imaging Components were $169 million, up 2 percent from the year-ago quarter.  Imaging Components second quarter gross orders were $205 million, up 14 percent from the year-ago quarter. "Strong panel business drove order and revenue growth for Imaging Components, offsetting weakness in the security and tube businesses," Wilson said. (For comparison purposes, a quarterly breakout of the Imaging Components segment financials for fiscal years 2014, 2013 and 2012 is attached.)

Other
The company's Other category, including the Varian Particle Therapy business and the Ginzton Technology Center, recorded second quarter revenues of $6 million versus $20 million in the year-ago quarter.  Gross orders for the Other category were $60 million for the second quarter, up from less than $1 million in the year-ago quarter.  The company recorded orders for proton installations at the Cincinnati Children's Hospital Medical Center in Ohio and at the Paul Scherrer Institute in Switzerland.  "This business gained good momentum during the quarter," Wilson said.

Outlook
"The company is continuing to execute well, and our businesses remain on track to reach our fiscal year 2014 growth targets," said Wilson.  "For the fiscal year, we continue to believe that total company revenues could increase by about six to eight percent over the prior fiscal year.  We expect net earnings per diluted share for the fiscal year, including the $0.16 effect of the patent litigation settlement, to be in the range of $4.06 to $4.18. We expect total company revenues for the third quarter of fiscal year 2014 to increase in the range of five to six percent.  We expect net earnings per diluted share for the third quarter to be in the range of $1.06 to $1.10."

Investor Conference Call
Varian Medical Systems is scheduled to conduct its second quarter fiscal year 2014 conference call at 2 p.m. PT today.  To hear a live webcast or replay of the call, visit the investor relations page on the company's web site at www.varian.com/investor where it will be archived for a year.  To access the call via telephone, dial 1-877-869-3847 from inside the U.S. or 1-201-689-8261 from outside the U.S.  The replay can be accessed by dialing 1-877-660-6853 from inside the U.S. or 1-201-612-7415 from outside the U.S. and entering confirmation code 13578961.  The telephone replay will be available through 5 p.m. PT, Friday, April 25, 2014.

Varian Medical Systems, Inc., of Palo Alto, California, is the world's leading manufacturer of medical devices and software for treating cancer and other medical conditions with radiotherapy, radiosurgery, and brachytherapy. The company supplies informatics software for managing comprehensive cancer clinics, radiotherapy centers and medical oncology practices. Varian is a premier supplier of tubes, digital detectors, and image processing software and workstations for X-ray imaging in medical, scientific, and industrial applications and also supplies high-energy X-ray devices for cargo screening and non-destructive testing applications.  Varian Medical Systems employs approximately 6,500 people who are located at manufacturing sites in North America, Europe, and China and approximately 70 sales and support offices around the world. For more information, visit http://www.varian.com or follow us on Twitter.

Forward-Looking Statements
Except for historical information, this news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements concerning industry outlook, including growth drivers; the company's future orders, revenues, backlog, or earnings growth; future financial results; market acceptance of or transition to new products or technology such as our Edge™ radiosurgery system, TrueBeam™ and radiographic flat panel detectors, image-guided radiation therapy, stereotactic radiosurgery, filmless X-rays, proton therapy, and security and inspection, and any statements using the terms "could," "should," "believe," "expect," "continue," "maintain," "outlook," "targets," or similar statements are forward-looking statements that involve risks and uncertainties that could cause the company's actual results to differ materially from those anticipated. Such risks and uncertainties include global economic conditions; the impact of  the Affordable Health Care for America Act (including excise taxes on medical devices) and any further healthcare reforms (including changes to Medicare and Medicaid), and/or changes in third-party reimbursement levels; currency exchange rates and tax rates; demand for the company's products; the company's ability to develop, commercialize, and deploy new products such as the TrueBeam platform; the company's ability to meet Food and Drug Administration (FDA) and other regulatory requirements for product clearances or to comply with FDA and other regulatory regulations or procedures; changes in the regulatory environment, including with respect to FDA requirements; challenges associated with the successful commercialization of the company's particle therapy business; the effect of adverse publicity; the company's reliance on sole or limited-source suppliers; the impact of reduced or limited demand by purchasers of certain X-ray products, including those located in Japan; the company's ability to maintain or increase margins; the impact of competitive products and pricing; the potential loss of key distributors or key personnel; challenges to public tender awards and the loss of such awards or other orders; and the other risks listed from time to time in the company's filings with the Securities and Exchange Commission, which by this reference are incorporated herein. The company assumes no obligation to update or revise the forward-looking statements in this release because of new information, future events, or otherwise.

A summary of earnings and other financial information follows.

 






Varian Medical Systems, Inc. and Subsidiaries
 Condensed Consolidated Statements of Earnings
 (Unaudited)

 



 

 

(Dollars and shares in millions, except per share amounts)


Q2 QTR

2014


Q2 QTR

2013 (1)


Q2 YTD

2014


Q2 YTD

2013 (1)




Gross orders

$

877.7


757.7


1,533.1


1,409.4




  Oncology Systems


613.0


576.9


1,146.3


1,085.7




  Imaging Components


205.0


180.1


326.4


322.3




  Other


59.7


0.7


60.4


1.4
















Net orders


818.6


735.8


1,427.6


1,355.0




  Oncology Systems


559.1


555.1


1,048.7


1,032.0




  Imaging Components


200.6


180.0


319.3


321.6




  Other


58.9


0.7


59.6


1.4
















Order Backlog


2,806.6


2,752.6


2,806.6


2,752.6
















Revenues


778.5


768.4


1,490.0


1,446.8




  Oncology Systems


603.1


581.8


1,144.5


1,106.1




  Imaging Components


169.0


166.4


330.2


316.4




  Other


6.4


20.2


15.3


24.3
















Cost of revenues


450.2


448.8


852.1


836.1
















Gross margin


328.3


319.6


637.9


610.7




  As a percent of revenues


42.2%


41.6%


42.8%


42.2%
















Operating expenses












  Research and development 


60.7


50.9


118.7


98.0




  Selling, general and administrative 


115.0


113.0


224.6


219.5




  Litigation Settlement 


25.1


-


25.1


-
















Operating earnings


127.5


155.7


269.5


293.2




  As a percent of revenues


16.4%


20.3%


18.1%


20.3%
















Interest income, net


0.6


0.6


1.0


1.3




Earnings before taxes


128.1


156.3


270.5


294.5




Taxes on earnings


35.4


43.5


79.8


86.4




Net earnings

$

92.7


112.8


190.7


208.1




  As a percent of revenues


11.9%


14.7%


12.8%


14.4%
















Net earnings per share – basic

$

0.89


1.04


1.82


1.91
















 Net earnings per share – diluted


0.88


1.02


1.79


1.88
















Shares used in the calculation of net earnings per share:    












Average shares outstanding - basic


104.2


108.8


105.0


109.0




Average shares outstanding - diluted


105.4


110.7


106.4


110.9
















(1)

Prior period numbers have been recast to conform to the segment reporting change.

 

 

 

Varian Medical Systems, Inc. and Subsidiaries

Condensed Consolidated Balance Sheets






(In thousands)


March 28,  


September 27,

2014

     2013  (1)

(Unaudited)


Assets





Current assets





    Cash and cash equivalents

$

938,997

$

1,117,861

    Short-term investment


79,444


62,700

    Accounts receivable, net


786,029


698,254

    Inventories                                       


561,194


535,223

    Deferred tax assets and other                                


312,640


290,745

Total current assets                                       


2,678,304


2,704,783






Property, plant and equipment                                             


750,109


715,991

    Accumulated depreciation and amortization                    


(424,267)


(400,660)

Property, plant and equipment, net                         


325,842


315,331






Goodwill


226,829


225,335

Other assets                                                    


244,863


223,025

Total assets                                              

$

3,475,838

$

3,468,474






Liabilities and Stockholders' Equity





Current liabilities                                                        





    Accounts payable                                             

$

170,364

$

194,272

    Accrued expenses                                             


370,525


320,884

    Deferred revenues                                              


418,247


389,479

    Advance payments from customers                              


169,905


160,644

    Product warranty                                                        


49,445


39,050

   Current maturities of long-term debt                              


56,250


56,250


Total current liabilities                                  


1,234,736


1,160,579

Other long-term liabilities


149,586


144,048

Long-term debt                                                             


412,500


450,000

Total liabilities                                          


1,796,822


1,754,627






Stockholders' Equity





Common stock


104,019


106,491

Capital in excess of par value


650,684


637,084

Retained earnings and accumulated other comprehensive loss 


924,313


970,272

Total stockholders' equity                                 


1,679,016


1,713,847

Total liabilities and stockholders' equity              

$

3,475,838

$

3,468,474



(1)

The condensed consolidated balance sheet as of September 27, 2013 was derived from audited financial statements as of that date. 

 

Varian Medical Systems, Inc. and Subsidiaries

Imaging Components

(Unaudited)







FY 2014


(In Millions)


Q114

Q214



FY 2014


Gross Orders

$

121.4

205.0



326.4


Net Orders


118.7

200.6



319.3


Revenues


161.2

169.0



330.2


Gross Margin                              

$

66.6

70.2



136.8



%

41.3

41.5



41.4


Operating Earnings                              

$

40.7

42.2



82.9















FY 2013


(In Millions)


  Q113

Q213

Q313

Q413

FY 2013


Gross Orders

$

142.2

180.1

144.6

201.3

668.2


Net Orders


141.6

180.0

143.1

201.2

665.9


Revenues


150.0

166.4

158.2

167.3

641.9


Gross Margin                              

$

61.2

70.4

64.8

71.7

268.1



%

40.8

42.3

41.0

42.8

41.8


Operating Earnings                              

$

35.2

43.5

40.2

46.7

165.6















FY 2012


(In Millions)


Q112

Q212

Q312

Q412

FY 2012


Gross Orders

$

120.9

174.6

126.5

174.4

596.4


Net Orders


120.5

174.5

126.2

174.3

595.5


Revenues


128.1

139.8

152.4

160.1

580.4


Gross Margin                              

$

50.4

58.9

66.2

66.9

242.4



%

39.3

42.1

43.4

41.8

41.8


Operating Earnings                              

$

28.4

34.0

39.0

41.1

142.5


















 

FOR INFORMATION CONTACT:

Elisha Finney (650) 424-6803
[email protected]

Spencer Sias (650) 424-5782
[email protected]

SOURCE Varian Medical Systems

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Extreme Computing is the ability to leverage highly performant infrastructure and software to accelerate Big Data, machine learning, HPC, and Enterprise applications. High IOPS Storage, low-latency networks, in-memory databases, GPUs and other parallel accelerators are being used to achieve faster results and help businesses make better decisions. In his session at 18th Cloud Expo, Michael O'Neill, Strategic Business Development at NVIDIA, focused on some of the unique ways extreme computing is...
"We're bringing out a new application monitoring system to the DevOps space. It manages large enterprise applications that are distributed throughout a node in many enterprises and we manage them as one collective," explained Kevin Barnes, President of eCube Systems, in this SYS-CON.tv interview at DevOps at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York City, NY.
Amazon has gradually rolled out parts of its IoT offerings in the last year, but these are just the tip of the iceberg. In addition to optimizing their back-end AWS offerings, Amazon is laying the ground work to be a major force in IoT – especially in the connected home and office. Amazon is extending its reach by building on its dominant Cloud IoT platform, its Dash Button strategy, recently announced Replenishment Services, the Echo/Alexa voice recognition control platform, the 6-7 strategic...
The best-practices for building IoT applications with Go Code that attendees can use to build their own IoT applications. In his session at @ThingsExpo, Indraneel Mitra, Senior Solutions Architect & Technology Evangelist at Cognizant, provided valuable information and resources for both novice and experienced developers on how to get started with IoT and Golang in a day. He also provided information on how to use Intel Arduino Kit, Go Robotics API and AWS IoT stack to build an application tha...
IoT generates lots of temporal data. But how do you unlock its value? You need to discover patterns that are repeatable in vast quantities of data, understand their meaning, and implement scalable monitoring across multiple data streams in order to monetize the discoveries and insights. Motif discovery and deep learning platforms are emerging to visualize sensor data, to search for patterns and to build application that can monitor real time streams efficiently. In his session at @ThingsExpo, ...
Ovum, a leading technology analyst firm, has published an in-depth report, Ovum Decision Matrix: Selecting a DevOps Release Management Solution, 2016–17. The report focuses on the automation aspects of DevOps, Release Management and compares solutions from the leading vendors.
Continuous testing helps bridge the gap between developing quickly and maintaining high quality products. But to implement continuous testing, CTOs must take a strategic approach to building a testing infrastructure and toolset that empowers their team to move fast. Download our guide to laying the groundwork for a scalable continuous testing strategy.
Adding public cloud resources to an existing application can be a daunting process. The tools that you currently use to manage the software and hardware outside the cloud aren’t always the best tools to efficiently grow into the cloud. All of the major configuration management tools have cloud orchestration plugins that can be leveraged, but there are also cloud-native tools that can dramatically improve the efficiency of managing your application lifecycle. In his session at 18th Cloud Expo, ...
SYS-CON Events announced today that LeaseWeb USA, a cloud Infrastructure-as-a-Service (IaaS) provider, will exhibit at the 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. LeaseWeb is one of the world's largest hosting brands. The company helps customers define, develop and deploy IT infrastructure tailored to their exact business needs, by combining various kinds cloud solutions.
Choosing the right cloud for your workloads is a balancing act that can cost your organization time, money and aggravation - unless you get it right the first time. Economics, speed, performance, accessibility, administrative needs and security all play a vital role in dictating your approach to the cloud. Without knowing the right questions to ask, you could wind up paying for capacity you'll never need or underestimating the resources required to run your applications.
Up until last year, enterprises that were looking into cloud services usually undertook a long-term pilot with one of the large cloud providers, running test and dev workloads in the cloud. With cloud’s transition to mainstream adoption in 2015, and with enterprises migrating more and more workloads into the cloud and in between public and private environments, the single-provider approach must be revisited. In his session at 18th Cloud Expo, Yoav Mor, multi-cloud solution evangelist at Cloudy...
SYS-CON Events announced today that 910Telecom will exhibit at the 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Housed in the classic Denver Gas & Electric Building, 910 15th St., 910Telecom is a carrier-neutral telecom hotel located in the heart of Denver. Adjacent to CenturyLink, AT&T, and Denver Main, 910Telecom offers connectivity to all major carriers, Internet service providers, Internet backbones and ...
StackIQ has announced the release of Stacki 3.2. Stacki is an easy-to-use Linux server provisioning tool. Stacki 3.2 delivers new capabilities that simplify the automation and integration of site-specific requirements. StackIQ is the commercial entity behind this open source bare metal provisioning tool. Since the release of Stacki in June of 2015, the Stacki core team has been focused on making the Community Edition meet the needs of members of the community, adding features and value, while ...
Big Data, cloud, analytics, contextual information, wearable tech, sensors, mobility, and WebRTC: together, these advances have created a perfect storm of technologies that are disrupting and transforming classic communications models and ecosystems. In his session at @ThingsExpo, Erik Perotti, Senior Manager of New Ventures on Plantronics’ Innovation team, provided an overview of this technological shift, including associated business and consumer communications impacts, and opportunities it ...
SYS-CON Events announced today that Venafi, the Immune System for the Internet™ and the leading provider of Next Generation Trust Protection, will exhibit at @DevOpsSummit at 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Venafi is the Immune System for the Internet™ that protects the foundation of all cybersecurity – cryptographic keys and digital certificates – so they can’t be misused by bad guys in attacks...